SDZ.SW SANDOZ GROUP N | CH1243598427
Company Profile
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
Latest News
Oil prices dip over 6% after US, Iran pause fighting over weekend
Reuters • 07/27/2026
Fractus and Geotab settle U.S. patent litigation
PR Newswire • 07/27/2026
Starcore Reports Year End 2026 Results
TMX Newsfile • 07/27/2026
Tredence Launches Domain Native Forward Deployed Engineering to Close the Last Mile of Enterprise AI
PR Newswire • 07/27/2026
Earnings To Watch: Corning (GLW) Reports Q2 Results Tomorrow
StockStory • 07/27/2026
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Website | https://www.sandoz.com |
| Audit Risk | 9 |
| Board Risk | 1 |
| Overall Risk | 2 |
| Market Cap | 27.53B |
| Trailing P/E | 37.2 |
| Forward P/E | 16.85 |
| Dividend Rate | 0.8 |
| Dividend Yield | 1.26% |
| Trailing Annual Div. Rate | 1.01 |
| Trailing Annual Div. Yield | 1.56% |
| Trailing EPS | 1.71 |
| Forward EPS | 3.78 |
| Book Value | 17.57 |
| Price-to-Book | 3.62 |
| Enterprise-to-Revenue | 2.82 |
| Enterprise-to-EBITDA | 16.64 |
| Ex-Dividend Date | 04/13/2026 |
| Dividend Date | 04/23/2025 |
| Earnings Date | |
| Earnings Call Date | |
| Revenue Average | 2.75B |
| Revenue Low | 2.75B |
| Revenue High | 2.75B |